# US 2017/0000817 A1 · Ionic aqueous compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0000817 A1
- Document ID: US20170000817A1
- Status: Published application
- Kind: A1
- Application number: 15/100,187
- Filed: 2014-11-28
- Published: 2017-01-05
- Earliest claimed: 2013-12-03
- Assignees: Gerolymatos International S.A.
- Applicants: Gerolymatos International S.A.
- Inventors: Konstantinos Alevizopoulos
- Web page: https://patentgrep.com/patent/US20170000817A1

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 35/748: Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina (algae, microalgae or microphytes A61K36/02)
- A61K 36/03: Phaeophycota or phaeophyta (brown algae), e.g. Fucus
- A61K 36/04: Rhodophycota or rhodophyta (red algae), e.g. Porphyra
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

## Claims

### Claim 1

A pharmaceutical composition comprising:
an ionic aqueous solution; and
a sulfated polysaccharide having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition of claim 1, wherein the sulfated polysaccharide is derived from an extract isolated from brown algae.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the brown algae is Undaria pinnafitida.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the sulfated polysaccharide is fucoidan.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the sulfated polysaccharide is in a range of about 0.1 to about 10% weight content of the composition.

### Claim 7

A pharmaceutical composition for nasal administration comprising:
an ionic aqueous solution; and
an extract from brown algae.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the brown algae extract is in a range of about 0.1 to about 10% weight content of the composition.

### Claim 9 (depends on 1)

The composition of claim 1 further comprising an extract of a blue/green algae.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the extract is isolated from Spirulina platensis.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the extract is in a range of about 0.1 to about 10% weight content of the composition.

### Claim at position 12

12-20. (canceled)

### Claim 21 (depends on 1)

The composition of claim 1, wherein the ionic aqueous solution comprises seawater.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the seawater comprises undiluted seawater.

### Claim 23 (depends on 21)

The composition of claim 21, wherein the seawater further comprises at least one of purified, distilled, deionized, and filtered water.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the ionic aqueous solution comprises saline.

### Claim 25 (depends on 1)

The composition of claim 1, wherein ionic aqueous solution is in a range of about 10 to about 99.9% weight content of the composition.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the composition has an osmolarity value ranging from about 250-350 mOsm/L for isotonic, greater than about 350 mOsm/L for hypertonic and less than about 250 mOsm/L for hypotonic.

### Claim 27 (depends on 1)

The composition of claim 1, further comprising at least one substance selected from essential oils and plant extracts.

### Claim at position 20

28-29. (canceled)

### Claim 30 (depends on 1)

A composition of claim 1 further comprising dexpanthenol as hydrating agent.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The composition of claim 30, wherein dexpanthenol is present at a concentration ranging from 0.25-2.5% w/w.

### Claim 33 (depends on 1)

A composition according to claim 1 selected from any one of Formulations 1-44 or a formulation of substantially similar composition.

### Claim at position 25

34-40. (canceled)

### Claim 41 (depends on 1)

A method for treating a respiratory tract and/or respiratory mucosal-related condition in a subject in need thereof, comprising aerosolizing a pharmaceutical composition of claim 1 in a nasal passageway of the subject.

### Claim 42

(canceled)

### Claim 43 (depends on 41)

The method of claim 41, wherein the respiratory tract and/or respiratory mucosal-related condition is selected from the group consisting of acute and chronic rhinosinusitis, sinusitis, allergic and non-allergic rhinitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and other diseases of the respiratory tract.

### Claim 44 (depends on 43)

The method of claim 43, wherein the respiratory tract and/or respiratory mucosal-related condition is rhinosinusitis or allergic rhinitis.

### Claim at position 30

45-48. (canceled)
